Cardio Diagnostics to Host Investor Conference Call on February 18

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Feb 11 2026

0mins

Should l Buy CDIO?

Cardio Diagnostics Holdings Inc. shares surged by 24.37% as the stock crossed above its 5-day SMA, reflecting strong investor interest.

The company will host an investor conference call on February 18, 2026, to provide updates on advancements in cardiovascular disease prevention and early detection, particularly focusing on its tests, Epi+Gen CHD™ and PrecisionCHD™. The call will also cover recent breakthrough clinical data and reimbursement progress, showcasing the company's strategic growth initiatives in precision cardiovascular medicine.

This conference call is expected to attract significant investor attention, highlighting Cardio Diagnostics' commitment to enhancing cardiovascular disease detection and management.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CDIO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CDIO

About CDIO

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Applied Optoelectronics Reports Strong Q4, Shares Surge

2 days agoBenzinga

Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.

Etsy Sells Depop to eBay for $1.2 Billion

Feb 19 2026Benzinga

Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.

Cardio Diagnostics to Host Investor Call on February 19, 2026

Feb 18 2026Businesswire

Investor Conference Call: Cardio Diagnostics will host an investor conference call on February 19, 2026, at 3 p.m. Central Time, aimed at providing updates on the company's advancements in cardiovascular disease prevention and early detection.
Product Updates: The call will cover the latest clinical data and reimbursement progress for the company's existing tests, Epi+Gen CHD™ and PrecisionCHD™, showcasing its innovative capabilities in precision cardiovascular medicine.
Technology-Driven Approach: Cardio Diagnostics leverages artificial intelligence and genomics to make cardiovascular disease prevention, detection, and management more personalized and precise, further advancing the development and commercialization of clinical tests.
Risk Factors Disclosure: The company notes in its statement that its future growth strategy may face various known and unknown risks and uncertainties, which could significantly impact its financial performance.